Stonehage Fleming Financial Services’s Elevance Health ELV Stock Holding History

Stonehage Fleming Financial Services’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.52M	Sell	11,677 -1,384	-11%	-$513K	0.15%	38
2026 Q1	$3.82M	Buy	13,061 +10,094	+340%	+$3.32M	0.14%	41
2025 Q4	$1.04M	Hold	2,967	–	–	0.03%	64
2025 Q3	$959K	Buy	2,967 +675	+29%	+$210K	0.03%	68
2025 Q2	$891K	Buy	+2,292	New	+$922K	0.03%	71
2025 Q1	–	Sell	-2,300	Closed	-$848K	–	210
2024 Q4	$848K	Buy	2,300 +394	+21%	+$165K	0.02%	66
2024 Q3	$991K	Sell	1,906 -7	-0.4%	-$3.74K	0.03%	59
2024 Q2	$1.04M	Buy	+1,913	New	+$1.01M	0.03%	53
2024 Q1	–	Sell	-1,917	Closed	-$904K	–	202
2023 Q4	$904K	Sell	1,917 -134	-7%	-$62K	0.03%	66
2023 Q3	$917K	Sell	2,051 -150	-7%	-$68K	0.08%	72
2023 Q2	$969K	Buy	+2,201	New	+$1.02M	0.04%	61
2022 Q3	–	Sell	-2,711	Closed	-$1.32M	–	213
2022 Q2	$1.32M	Sell	2,711 -145	-5%	-$71.7K	0.05%	52
2022 Q1	$1.43M	Hold	2,856	–	–	0.04%	57
2021 Q4	$1.33M	Hold	2,856	–	–	0.04%	68
2021 Q3	$1.11M	Hold	2,856	–	–	0.03%	72
2021 Q2	$1.09M	Sell	2,856 -200	-7%	-$76.4K	0.03%	72
2021 Q1	$1.11M	Buy	3,056 +298	+11%	+$95.8K	0.04%	74
2020 Q4	$866K	Hold	2,758	–	–	0.03%	82
2020 Q3	$716K	Hold	2,758	–	–	0.03%	81
2020 Q2	$715K	Hold	2,758	–	–	0.05%	66
2020 Q1	$636K	Sell	2,758 -478	-15%	-$130K	0.03%	77
2019 Q4	$988K	Buy	3,236 +409	+14%	+$113K	0.04%	65
2019 Q3	$679K	Hold	2,827	–	–	0.03%	82
2019 Q2	$797K	Hold	2,827	–	–	0.04%	71
2019 Q1	$811K	Hold	2,827	–	–	0.04%	74
2018 Q4	$742K	Hold	2,827	–	–	0.04%	82
2018 Q3	$775K	Hold	2,827	–	–	0.05%	87
2018 Q2	$673K	Buy	2,827 +974	+53%	+$226K	0.03%	102
2018 Q1	$407K	Hold	1,853	–	–	0.03%	130
2017 Q4	$417K	Hold	1,853	–	–	0.02%	138
2017 Q3	$352K	Hold	1,853	–	–	0.02%	153
2017 Q2	$348K	Sell	1,853 -432	-19%	-$77.6K	0.02%	151
2017 Q1	$378K	Hold	2,285	–	–	0.02%	182
2016 Q4	$329K	Sell	2,285 -202	-8%	-$27K	0.02%	186
2016 Q3	$312K	Hold	2,487	–	–	0.02%	176
2016 Q2	$327K	Sell	2,487 -2,268	-48%	-$310K	0.02%	161
2016 Q1	$661K	Buy	+4,755	New	+$635K	0.04%	123
2015 Q4	–	Sell	-605	Closed	-$85K	–	128
2015 Q3	$85K	Sell	605 -2,875	-83%	-$432K	0.01%	112
2015 Q2	$571K	Hold	3,480	–	–	0.07%	63
2015 Q1	$537K	Hold	3,480	–	–	0.06%	68
2014 Q4	$437K	Buy	+3,480	New	+$430K	0.05%	73

Other funds holding ELV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Stonehage Fleming Financial Services's ELV Position: Q2 2026 in Review

Stonehage Fleming Financial Services reduced its Elevance Health (ELV) stake by 11% in Q2 2026, selling an estimated $513K and leaving 11,677 shares worth $4.52M. The position accounts for 0.15% of the portfolio, ranked #38.

Stonehage Fleming Financial Services first reported a position in ELV in Q4 2014 and has held it in 41 quarters since. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

Stonehage Fleming Financial Services held 11,677 shares of Elevance Health worth $4.52M as of Q2 2026.
Stonehage Fleming Financial Services sold 1,384 Elevance Health shares in Q2 2026, an estimated $513K.
Elevance Health made up 0.15% of Stonehage Fleming Financial Services's portfolio in Q2 2026, its #38 holding.
Stonehage Fleming Financial Services first reported a position in Elevance Health in Q4 2014 and has held it in 41 quarters since.
1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Stonehage Fleming Financial Services's 13F filing for Q2 2026, filed 17 Aug 2026.